KURA ONCOLOGY INC. -

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

04 1 2024 10:14:50 提供 NetDania Notify

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

02 1 2024 09:09:11 提供 NetDania Notify

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

08 12 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

28 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2023 Financial Results

02 11 2023 15:01:00 提供 Nasdaq GlobeNewswire

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

02 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

30 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2023 Financial Results

26 10 2023 15:05:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

19 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

17 10 2023 15:05:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

28 9 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

19 9 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

14 8 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2023 Financial Results

03 8 2023 15:05:03 提供 Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2023 Financial Results

27 7 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

14 6 2023 06:00:01 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

13 6 2023 15:01:00 提供 Nasdaq GlobeNewswire

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

11 6 2023 02:45:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

30 5 2023 06:30:00 提供 Nasdaq GlobeNewswire